Loading clinical trials...
Loading clinical trials...
Prospective Evaluation of a Proteomic Signature Developed to Identify Patients Likely to Benefit From Erlotinib (TarcevaTM), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Used in the Treatment of Non-small Cell Lung Cancer
Conditions
Locations
7
Ireland
Cork University Hospital
Cork, Ireland
Beaumont Hospital
Dublin, Ireland
St James Hospital
Dublin, Ireland
The Adelaide & Meath Hospital, Dublin, Incorporating the National Children's Hospital
Dublin, Ireland
Galway University Hospital
Galway, Ireland
Mid-Western Regional Hospital
Limerick, Ireland
Start Date
December 1, 2009
Primary Completion Date
August 1, 2013
Last Updated
March 30, 2015
NCT07190248
NCT06305754
NCT07100080
NCT07195695
NCT06357533
NCT06731413
Lead Sponsor
Cancer Trials Ireland
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions